RxDoctor Payments Data

Glenn Rubin, MD

Internal Medicine · Boca Raton, FLNPI 1326018615

Payments from drug & device makers

$918in general payments, 2019–2025

Across 48 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$219
  • Amgen$174
  • Pfizer$129
  • Exact Sciences$65
  • Lilly USA, LLC$51
  • Novartis$49
  • plus $231 from 10 others

What the payments were for

  • Food & beverage$918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$918 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$388,982
Medicare patients
484
Services billed
13,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$180,865
Repatha SureclickEvolocumab98$82,484
JardianceEmpagliflozin65$67,893
OzempicSemaglutide61$55,205
XareltoRivaroxaban29$45,003
PercocetOxycodone Hcl/Acetaminophen13$44,900
JanuviaSitagliptin Phosphate36$44,645
MounjaroTirzepatide27$28,057
FarxigaDapagliflozin Propanediol21$24,419
LivaloPitavastatin Calcium31$23,712
EntrestoSacubitril/Valsartan11$22,460
Breo ElliptaFluticasone/Vilanterol38$19,056
Repatha SyringeEvolocumab21$14,992
Praluent PenAlirocumab15$14,343
TrulicityDulaglutide13$13,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$180,865161 claims
Novo NordiskOzempic, Rybelsus$219$66,72273 claims
Lilly USA, LLCMounjaro, Trulicity$51$41,57540 claims
Kowa Pharmaceuticals America, Inc.Livalo$17$23,71231 claims
NovartisEntresto$49$22,46011 claims
GSKBreo Ellipta$25$19,05638 claims
AbbVieSynthroid$14$4,75851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →